“`html
Strengthening the Response to MPOX in France: A Strategic Update
Table of Contents
- 1 Strengthening the Response to MPOX in France: A Strategic Update
- 2 Understanding Mpox Virus and Vaccination Strategies
- 3 The Sanitary Authorities Strengthen the Vaccinal Strategy to Fight Mpox
- 4 Strengthening the Response to MPOX in France: A Strategic Update
- 5 Awareness and Actions Against Mpox Virus
September 4, 2024
In light of the Public Health Emergency of International Concern (USPPI) declared by the World Health Organization (WHO) regarding MPOX in Africa, France’s Ministry of Labour, Health and Solidarity is intensifying its strategy to combat the virus. This is in alignment with the ongoing efforts initiated in 2022.
Since the initial outbreak declared in 2022, MPOX type 2 has been closely monitored as it spreads quietly across the country. From January 1 to September 3, 2024, there have been 143 reported cases of MPOX clade 2. Concurrently, an epidemic of type 1 MPOX, especially clade 1b, has been circulating in Central African countries, particularly in the Democratic Republic of the Congo and its neighboring regions. To date, only one case of clade 1b has been detected in Europe (Sweden).
The Ministry’s Adjusted Response Goals Include:
- Reducing the circulation of clade 2 in France.
- Enhancing the long-term immunity of the population.
- Preventing the emergence of clade 1b in France.
Health officials have continued the MPOX vaccination program since 2022. Current strategies focus on:
- Targeting high-risk groups through preventive pre-exposure vaccination campaigns.
- Implementing reactive vaccination strategies for contacts of high-risk groups around MPOX cases.
According to the High Authority of Health (HAS), the target groups for preventive vaccination include:
- Men who have sex with men (MSM) with multiple partners.
- Transgender individuals engaging with multiple partners.
- Sex workers and professionals in sex consumption establishments.
- Partners or individuals sharing living spaces with high-risk individuals.
Health authorities advise these groups to:
- Initiate or complete their vaccination regimen, which consists of 3 doses for immunocompromised persons and 1 dose for those previously vaccinated.
- Receive booster vaccinations if they completed their vaccination schedule in 2022 (excluding childhood vaccinations).
For individuals who have been infected between 2022 and now, vaccination is not recommended.
In addition, the upcoming opinion from the High Council for Public Health (HCSP) will provide guidance for travelers, caregivers, and humanitarian workers regarding risky sexual behaviors in MPOX type 1 active areas. This will also include advice for individuals traveling from regions with MPOX clade 1 to visit family and receive vaccinations.
Since 2022, France has offered vaccination services nationwide. New vaccination slots will soon be available to ensure that all eligible individuals can receive their vaccines, free of charge.
Health authorities emphasize that alongside vaccination, screening and preventive measures remain crucial in the fight against MPOX, including adherence to health guidelines, isolation of infected cases, and maintaining barrier measures.
If you experience suggestive symptoms of MPOX, seek medical attention promptly.
“““html
Understanding Mpox Virus and Vaccination Strategies
What You Need to Know About Mpox
Mpox, characterized by fever and rash with blisters, necessitates immediate attention if symptoms occur. Individuals experiencing these symptoms should reach out to their general practitioner or contact the Free Information, Screening and Diagnostic Center (Cegidd) promptly.
The French public health department has established a confidential “mpox information service” hotline at 0 801 30 80 69. This service is available for anonymous inquiries from 8 am to 11 pm daily, ensuring everyone can access necessary information.
Strengthening the Vaccine Strategy
The health authorities are actively reinforcing their vaccination strategy to combat mpox. For up-to-date information, consult the following resources:
“““html
The sanitary authorities are enhancing their vaccination strategy against Mpox to mitigate the spread of the disease. This initiative reflects the growing need to address public health challenges through effective vaccination campaigns.
In response to the Mpox outbreak, health officials are implementing comprehensive measures to ensure widespread vaccination. This includes increasing public awareness and accessibility to vaccines, providing necessary information to the community, and collaborating with healthcare providers to facilitate the vaccination process.
Mpox Information Service
For further information regarding Mpox, individuals can contact the Mpox Information Service at 0 801 90 80 69 or visit mpox-info-service.fr.
Health Crisis Center Contact
For inquiries, please reach out to the Health Crisis Center of the Ministry of Labour, Health and Solidarity:
Email: alerts-presse@sante.gouv.fr
Phone: 01 87 05 93 80
Stay Informed
It is crucial for the public to stay informed about vaccination campaigns and health guidelines related to Mpox. Regular updates will be provided by local health authorities to ensure everyone is aware of the available resources and vaccination opportunities.
“`
Strengthening the Response to MPOX in France: A Strategic Update
September 4, 2024
In light of the Public Health Emergency of International Concern (USPPI) declared by the World Health Organization (WHO) regarding MPOX in Africa, France’s Ministry of Labour, Health and Solidarity is intensifying its strategy to combat the virus. This is in alignment with the ongoing efforts initiated in 2022.
Since the initial outbreak declared in 2022, MPOX type 2 has been closely monitored as it spreads quietly across the country. From January 1 to September 3, 2024, there have been 143 reported cases of MPOX clade 2. Concurrently, an epidemic of type 1 MPOX, especially clade 1b, has been circulating in Central African countries, particularly in the Democratic Republic of the Congo and its neighboring regions. To date, only one case of clade 1b has been detected in Europe (Sweden).
The Ministry’s Adjusted Response Goals Include:
- Reducing the circulation of clade 2 in France.
- Enhancing the long-term immunity of the population.
- Preventing the emergence of clade 1b in France.
Health officials have continued the MPOX vaccination program since 2022. Current strategies focus on:
- Targeting high-risk groups through preventive pre-exposure vaccination campaigns.
- Implementing reactive vaccination strategies for contacts of high-risk groups around MPOX cases.
Target Groups for Preventive Vaccination
According to the High Authority of Health (HAS), the target groups for preventive vaccination include:
- Men who have sex with men (MSM) with multiple partners.
- Transgender individuals engaging with multiple partners.
- Sex workers and professionals in sex consumption establishments.
- Partners or individuals sharing living spaces with high-risk individuals.
Health authorities advise these groups to:
- Initiate or complete their vaccination regimen, which consists of 3 doses for immunocompromised persons and 1 dose for those previously vaccinated.
- Receive booster vaccinations if they completed their vaccination schedule in 2022 (excluding childhood vaccinations).
For individuals who have been infected between 2022 and now, vaccination is not recommended.
In addition, the upcoming opinion from the High Council for Public Health (HCSP) will provide guidance for travelers, caregivers, and humanitarian workers regarding risky sexual behaviors in MPOX type 1 active areas. This will also include advice for individuals traveling from regions with MPOX clade 1 to visit family and receive vaccinations.
Since 2022, France has offered vaccination services nationwide. New vaccination slots will soon be available to ensure that all eligible individuals can receive their vaccines, free of charge.
Health authorities emphasize that alongside vaccination, screening and preventive measures remain crucial in the fight against MPOX, including adherence to health guidelines, isolation of infected cases, and maintaining barrier measures.
If you experience suggestive symptoms of MPOX, seek medical attention promptly.
Awareness and Actions Against Mpox Virus
Understanding Mpox Virus and Vaccination Strategies
What You Need to Know About Mpox
Mpox, characterized by fever and rash with blisters, necessitates immediate attention if symptoms occur. Individuals experiencing these symptoms should reach out to their general practitioner or contact the Free Information, Screening and Diagnostic Center (Cegidd) promptly.
The French public health department has established a confidential “mpox information service” hotline at 0 801 30 80 69. This service is available for anonymous inquiries from 8 am to 11 pm daily, ensuring everyone can access necessary information.
Strengthening the Vaccine Strategy
The health authorities are actively reinforcing their vaccination strategy to combat mpox. For up-to-date information, consult the following resources:
